Actively Recruiting
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-02-17
375
Participants Needed
7
Research Sites
155 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
T
The Leukemia and Lymphoma Society
Collaborating Sponsor
AI-Summary
What this Trial Is About
The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL) and works as well as the standard dose of radiation therapy. The researchers will see if VLDRT works against cancer in the area that is currently affected by cancer and if the therapy prevents new spots of lymphoma from developing. The researchers will also compare VLDRT with the standard dose of radiation therapy to see if VLDRT causes fewer side effects. Radiation therapy uses beams of intense energy to kill cancer cells. Standard doses of radiation therapy can cause short- and long-term side effects. Researchers think VLDRT may be as effective as standard doses, and, because VLDRT uses less radiation, researchers think VLDRT may cause fewer side effects than standard doses.
CONDITIONS
Official Title
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with follicular lymphoma or marginal zone lymphoma as defined by WHO 5th Edition or ICC criteria
- Stage I or II disease involving one or two or more nodal regions on the same side of the diaphragm
- Newly diagnosed or previously observed without prior lymphoma-directed therapy
- For localized gastric MALT lymphoma, documented negative H. Pylori test within 6 months before radiation
- Age 18 years or older at enrollment
- Able to start radiation within 2 months from randomization
You will not qualify if you...
- Prior radiation to the site(s) needing treatment
- Follicular lymphoma grade 3B or follicular large B cell lymphoma
- Planned concurrent systemic therapy, including oral steroids, for lymphoma
- Cutaneous only indolent non-Hodgkin lymphoma (primary cutaneous B-cell lymphoma, follicle center lymphoma, marginal zone lymphoma, or unspecified skin lymphoma)
- Complete surgical removal of all disease
- Tumor size 5 cm or larger in maximum diameter
- Any medical or psychiatric condition that would make participation inappropriate in the investigator's judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
B
Brandon Imber, MD
CONTACT
J
Joachim Yahalom, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here